Telix Announces Board Renewal
Telix today announces new Director appointments as part of a Board succession planning and renewal process.
Illuccix® Approved in Norway
Telix today announces that its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing authorization by NOMA for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, a broad clinical label.
Telix 2024 Full Year Results: Record Financial Performance and Investment in Future Growth, FY2025 Guidance of up to $1.23 Billion
Telix today announces its financial results for the year ended 31 December 2024.
Illuccix® Approved in the United Kingdom
Telix today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection).
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform
Telix today announces it has completed the acquisition from antibody engineering company ImaginAb, Inc. (ImaginAb). The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities.
Telix Completes Acquisition of RLS (USA) Inc.
Telix today announces it has completed the acquisition of RLS (USA) Inc. (RLS; RLS Radiopharmacies), America’s only Joint Commission-accredited radiopharmacy network distributing PET, SPECT and therapeutic radiopharmaceuticals.
Illuccix® Receives European Approval
Telix today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).
Telix Exceeds FY24 Guidance with US$142M Q4 Revenue
Telix today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 (Q4 2024).
Telix Files TLX250-CDx (Zircaix®) BLA for Kidney Cancer Imaging
Telix today announces that it has submitted its Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX250-CDx (Zircaix®, 89Zr- girentuximab) kidney cancer imaging).
Telix to Add FAP-Targeting Candidates to Theranostic Pipeline
Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program will initially focus on the treatment of bladder cancer, rounding out its urology franchise, which includes late-stage therapeutic programs for kidney and prostate cancers.